Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial.

MLA

Li, Xiao, et al. “Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial.” Clinical Drug Investigation, vol. 41, no. 8, Aug. 2021, pp. 685–99. EBSCOhost, https://doi.org/10.1007/s40261-021-01057-y.

APA

Li, X., Bilcke, J., van der Velden, A. W., Bongard, E., Bruyndonckx, R., Sundvall, P.-D., Harbin, N. J., Coenen, S., Francis, N., Bruno, P., Garcia-Sangenis, A., Glinz, D., Kosiek, K., Mikó-Pauer, R., Radzeviciene Jurgute, R., Seifert, B., Tsakountakis, N., Aabenhus, R., Butler, C. C., & Beutels, P. (2021). Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial. Clinical Drug Investigation, 41(8), 685–699. https://doi.org/10.1007/s40261-021-01057-y

Chicago

Li, Xiao, Joke Bilcke, Alike W. van der Velden, Emily Bongard, Robin Bruyndonckx, Pär-Daniel Sundvall, Nicolay J. Harbin, et al. 2021. “Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial.” Clinical Drug Investigation 41 (8): 685–99. doi:10.1007/s40261-021-01057-y.